Stock News

Gilman Hill Asset Management Lowered By $377,832 Its Douglas Dynamics (PLOW) Stake; HUMANIGEN (HGEN) Shorts Down By 58.97%

HUMANIGEN INCORPORATED (OTCMKTS:HGEN) had a decrease of 58.97% in short interest. HGEN’s SI was 3,200 shares in February as released by FINRA. Its down 58.97% from 7,800 shares previously. With 7,600 avg volume, 0 days are for HUMANIGEN INCORPORATED (OTCMKTS:HGEN)’s short sellers to cover HGEN’s short positions. The stock increased 16.67% or $0.09 during the last trading session, reaching $0.63. About 28,497 shares traded or 27.04% up from the average. Humanigen, Inc. (OTCMKTS:HGEN) has 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Gilman Hill Asset Management Llc decreased Douglas Dynamics Inc (PLOW) stake by 5.54% reported in 2017Q3 SEC filing. Gilman Hill Asset Management Llc sold 9,688 shares as Douglas Dynamics Inc (PLOW)’s stock declined 13.35%. The Gilman Hill Asset Management Llc holds 165,268 shares with $6.51M value, down from 174,956 last quarter. Douglas Dynamics Inc now has $849.42 million valuation. The stock decreased 1.05% or $0.4 during the last trading session, reaching $37.6. About 72,003 shares traded. Douglas Dynamics, Inc. (NYSE:PLOW) has risen 44.70% since February 17, 2017 and is uptrending. It has outperformed by 28.00% the S&P500.

Humanigen, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States. The company has market cap of $9.42 million. The companyÂ’s lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. It currently has negative earnings. It is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies.

Since August 30, 2017, it had 0 buys, and 4 insider sales for $4.11 million activity. On Friday, January 5 McCormick Robert L sold $601,125 worth of Douglas Dynamics, Inc. (NYSE:PLOW) or 15,000 shares. The insider Janik James L sold 15,593 shares worth $586,923.

Investors sentiment increased to 1.2 in 2017 Q3. Its up 0.32, from 0.88 in 2017Q2. It improved, as 10 investors sold PLOW shares while 36 reduced holdings. 20 funds opened positions while 35 raised stakes. 19.75 million shares or 2.63% more from 19.25 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) owns 658 shares for 0% of their portfolio. Mondrian Prtnrs Ltd holds 0.06% or 57,548 shares in its portfolio. Qs Invsts Ltd Liability Corporation owns 1,670 shares for 0% of their portfolio. Royal Bancshares Of Canada reported 21,522 shares stake. Moreover, First Merchants Corp has 0.05% invested in Douglas Dynamics, Inc. (NYSE:PLOW) for 7,750 shares. 1.36 million were accumulated by Wells Fargo & Com Mn. Anchor Cap Advisors Limited Company holds 0.04% or 25,497 shares. North Star Mngmt stated it has 104,486 shares. Capital Ww Investors stated it has 1.63 million shares. Aqr Cap Limited Co holds 23,058 shares or 0% of its portfolio. Deutsche National Bank Ag has invested 0.01% in Douglas Dynamics, Inc. (NYSE:PLOW). Systematic Mngmt Limited Partnership accumulated 312,539 shares. State Street accumulated 0% or 441,530 shares. Conestoga Capital Advisors Ltd Liability Com reported 567,400 shares. The Ontario – Canada-based Toronto Dominion Comml Bank has invested 0% in Douglas Dynamics, Inc. (NYSE:PLOW).

Leave a Reply

Your email address will not be published. Required fields are marked *